Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Renin-Angiotensin-System (RAS)-Acting Agents Market’s Growth Trajectory From 2025 To 2034?

The market for agents acting on the renin-angiotensin-system (RAS) has witnessed consistent growth over the past few years. Its size is projected to increase from $5.82 billion in 2024 to $6.11 billion in 2025, registering a compound annual growth rate (CAGR) of 5.0%. The growth witnessed during the historical period can be explained by a rise in hypertension cases, an increase in cardiovascular diseases, the steadily growing aged population, heightened awareness regarding blood pressure regulation, robust backing from clinical research, and regulatory clearance for fresh medications.

The market size of agents acting on the renin-angiotensin-system (RAS) is predicted to witness robust growth in the coming years, propelling it to a value of $7.55 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The increasing concentration on customised treatments, a surge in the demand for fixed-dose combinations, raising funds towards cardiovascular research, broadening access to healthcare in emerging markets, and the rising prevalence of diseases tied to lifestyle factors are all contributors to the forecasted growth. During the forecasted period, key trends expected to emerge include drug development powered by artificial intelligence (AI), nanotechnology-driven drug delivery systems, advancements in personalized medicine, the use of blockchain for safeguarding clinical data, hypertension monitoring through wearable biosensors, and the application of digital twin technology for modelling patients.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What External and Internal Drivers Are Contributing to the Growth of theRenin-Angiotensin-System (RAS)-Acting Agents Market?

The rising occurrence of hypertension is anticipated to stimulate the development of the renin-angiotensin system (RAS)-acting agents market. Hypertension is a long-term health condition characterized by continuously elevated blood pressure against the arterial walls. The surge in hypertension cases can be attributed to poor nutrition habits, particularly excessive salt and processed food intake that leads to increased blood pressure and puts pressure on the heart. The RAS-acting agents help in the control of hypertension by regulating blood pressure through the suppression of angiotensin II, a hormone that narrows blood vessels and increases fluid retention, leading to vasodilation and decreased blood pressure. For example, data from the Australian Bureau of Statistics in October 2024 indicated that in 2022, 11.6% (3.0 million) of Australians suffered from hypertension, with comparable rates in males (11.7%) and females (11.6%). Hence, the growing occurrence of hypertension is fuelling the expansion of the renin-angiotensin system (RAS)-acting agents market.

What Segment Types Define the Renin-Angiotensin-System (RAS)-Acting Agents Market Structure?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Renin-Angiotensin-System (RAS)-Acting Agents Market?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Renin-Angiotensin-System (RAS)-Acting Agents Market?

Leading firms in the renin-angiotensin system (RAS) agents market are prioritizing the creation of unique RAS blockers, such as angiotensin-converting enzyme (ACE) inhibitors. These efforts aim to boost efficacy, curtail adverse reactions, enhance patient adherence, and address health conditions like hypertension, cardiac failure, and renal diseases. An ACE inhibitor acts as a medication that reduces blood pressure by inhibiting the enzyme responsible for converting angiotensin I into angiotensin II, a compound that constricts blood vessels. In November of 2023, Proveca Ltd., a pharmaceutical organization based in the UK, was awarded a grant by the European Commission for pediatric use marketing authorization (PUMA) for its product, Aqumeldi (enalapril maleate) orodispersible tablets. These tablets, intended for infants to individuals under 18 years, are used for heart failure treatment. Aqumeldi, an ACE inhibitor, benefits children suffering from cardiac failure by obstructing the angiotensin-converting enzyme (ACE), thereby preventing the changing of angiotensin I into angiotensin II. This process aids in blood vessel dilation, improved blood circulation, and reduced heart stress.

View the full report here:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

What Is the Definition of the Renin-Angiotensin-System (RAS)-Acting Agents Market?

The renin-angiotensin system (RAS)-acting agents are a class of medications that regulate blood pressure, fluid balance, and vascular resistance by targeting various components of the renin-angiotensin system, which plays a crucial role in cardiovascular and renal function. These agents are commonly prescribed to treat conditions like hypertension, heart failure, and chronic kidney disease by either blocking the production of angiotensin II or inhibiting its effects on blood vessels.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23496

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model